Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
Crowdfunder has an online community of over 600,000 and has raised over £40 million for over 15,000 projects since 2012 making them the #1 rewards-based crowdfunding platform. They are now EBITDA positive and have plans to further automate their platform, as well as grow their partner network.
days to go:
Expired
investment:
£1,114,040
Oval Money is the leading European automated saving and crowd investing marketplace that brings simple access and diversification to investment solutions for people who don't have large sums of initial capital. The company is backed by major VC investors and supported by the largest banks in Europe.
days to go:
Expired
investment:
£626,310
Assetz Exchange ('AE') offers an efficient way for retail investors to invest and trade in housebuilding projects residential property for both income and capital growth. AE allows investors to produce a customised property portfolio in minutes. The company has launched its website in May 2019, and it is fully live. The funds will be used for the development of the website, development of the property, hiring team members and for launching marketing and PR.
days to go:
Expired
investment:
£690,453
Assetz Capital is a leading property-secured business marketplace lender in the UK and Europe. It provides loans to small and medium enterprises (SMEs), and property developers in the UK, financed by retail investors, institutional investors, government bodies and banks. The company has arranged loans of over £1 billion since its founding in April 2013. It ranked 53rd out of the UK’s top 100 fastest-growing technology companies for two consecutive years in the Sunday Times Tech Track 100, and funded the equivalent of 1 in 100 UK homes in the last two years. Assetz Capital aims to utilise the investment to fund legal and structuring work around the Coronavirus Business Interruption Loan Schemes (CBILS), have working capital for business development, grow its team, and possibly launch an Initial Public Offering (IPO) in the future.
days to go:
Expired
investment:
£760,600
